NEWS RELEASES

Search all of our news releases here.

Try these: Jeff GalvinC. David PauzaHIVFDAAmerican Gene Technologies

American Gene Technologies announces CEO Jeff Galvin will attend the 38th annual J.P. Morgan Healthcare Conference

American Gene Technologies To Attend J.P. Morgan Healthcare Conference 2020

Jan 8, 2020

ROCKVILLE, MD, January 8, 2020 – American Gene Technologies announced today that its Chief Executive Officer, Jeff Galvin, will attend the 38th annual J.P. Morgan Healthcare Conference, held at the Westin St. Francis between January 12-16 in San Francisco, California. American Gene Technologies’ second invitation…

Read More
American Gene Technologies Hosts Celebration Event For Its First IND Submission (For HIV) To The Food and Drug Administration (FDA)

American Gene Technologies Hosts Celebration Event For Its First IND Submission (For HIV) To The Food and Drug Administration (FDA)

Nov 6, 2019

Press release also featured on:  GlobeNewswire.com ROCKVILLE, MD, November 06, 2019 – American Gene Technologies (AGT) announced today it will host a red carpet event tonight to celebrate a significant milestone in the company’s 11-year history of scientific research in cell and gene therapy: AGT successfully…

Read More
IND Application Submission To FDA For Phase 1 Trial Of Genetically Modified Autologous Cell Therapy For HIV Announced by American Gene Technologies

IND Application Submission To FDA For Phase 1 Trial Of Genetically Modified Autologous Cell Therapy For HIV Announced by American Gene Technologies

Oct 18, 2019

ROCKVILLE, Md., Oct. 18, 2019 /PRNewswire/ — American Gene Technologies (AGT) announced today the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for AGT’s lead HIV program, AGT103-T, which is potentially a single-dose, lentiviral vector-based gene therapy developed for the purpose of eliminating HIV from people infected with the…

Read More
American Gene Technologies to Present at 2019 Cell & Gene Meeting on the Mesa

American Gene Technologies to Present at 2019 Cell & Gene Meeting on the Mesa

Oct 2, 2019

ROCKVILLE, Md., Oct. 01, 2019 (GLOBE NEWSWIRE) — American Gene Technologies announced today that its Chief Science Officer C. David Pauza, Ph.D. will present at the annual Cell & Gene Meeting on the Mesa to be held October 2-4 in Carlsbad, California. Organized by the…

Read More
HIV Cure Program of American Gene Technologies Adds University of Maryland School of Medicine’s Institute of Human Virology as New Study Site to Support the Development of a Cell and Gene Therapy for HIV

HIV Cure Program of American Gene Technologies Adds University of Maryland School of Medicine’s Institute of Human Virology as New Study Site to Support the Development of a Cell and Gene Therapy for HIV

Jul 2, 2019

ROCKVILLE, Md. — American Gene Technologies (AGT), a leading gene and cell therapy company based in Rockville, MD, selected the Institute of Human Virology (IHV) at the University of Maryland School of Medicine (UMSOM) as a new clinical site for its non-IND study, AGT-CS168, to…

Read More
HIV Cure Program Patent Granted To American Gene Technologies

HIV Cure Program Patent Granted To American Gene Technologies

May 21, 2019

ROCKVILLE, Md., May 21, 2019 (GLOBE NEWSWIRE) — American Gene Technologies, a leading gene and cell therapy company based in Rockville, Md., was granted a second patent for its unique molecule, methods, and cell process for its HIV program. This patent further protects AGT’s lentiviral vector and…

Read More
AGT Launches Oncology Science Advisory Group to Accelerate Research For A Cancer Cure

AGT Launches Oncology Science Advisory Group to Accelerate Research For A Cancer Cure

Mar 25, 2019

ROCKVILLE, MD, UNITED STATES, March 25, 2019 /EINPresswire.com/ — American Gene Technologies (AGT), a leading gene and cell therapy biotech company based in Rockville, Md., has established an advisory group for the advancement of immunotherapies that activate gamma-delta (γδ) T cells to attack a variety…

Read More
AGT Granted Fifth Patent Protecting Its Immunotherapy Cancer Cure Asset

AGT Granted Fifth Patent Protecting Its Immunotherapy Cancer Cure Asset

Mar 21, 2019

ROCKVILLE, MD, UNITED STATES, March 21, 2019 /EINPresswire.com/ — American Gene Technologies (AGT) recently was awarded a fifth immuno-oncology patent (“Methods and Composition for the Activation of Gamma Delta T cells” US10137144) to protect its lead asset in immunotherapy for cancer. This patent further validates the advances AGT…

Read More
Second Patient Cured of HIV and The Implications for American Gene Technologies's AGT103-T

Second Patient Cured of HIV and The Implications for American Gene Technologies’s AGT103-T

Mar 9, 2019

ROCKVILLE, MD, UNITED STATES, March 8, 2019 / American Gene Technologies (AGT) is pleased to see the release of information about a second individual cured of HIV in London–recently reported in the Wall Street Journal and New York Times. The patient was treated with a…

Read More
American Gene Technologies Signs Research Agreement with NIAID for Experimental HIV/AIDS Cure Strategy

American Gene Technologies Signs Research Agreement with NIAID for Experimental HIV/AIDS Cure Strategy

Feb 14, 2019

AGT signed Research Collaboration Agreement with National Institute of Allergy and Infectious Diseases for studies on AGT’s cell and gene therapy for HIV/AIDS. ROCKVILLE, MD, UNITED STATES, February 14, 2019 /EINPresswire.com/ — American Gene Technologies (AGT) recently signed a Research Collaboration Agreement with the National…

Read More

Subscribe to News Releases and News Updates

Subscribe to our news release and published article updates to be notified when we release new content!

Follow AGT on Social Media

AGT on Facebook

Tune in to Cell & Gene: The Podcast and hear Addimmune's Dr. Marcus Conant, a pioneer in HIV research, discuss our innovative cell therapy for HIV. He shares his vision for empowering patients and transforming HIV treatment. loom.ly/96TZ0jU#HIV #celltherapy #biotech ... See MoreSee Less
View on Facebook
M&A has been steady in 2024. We count 47 private & public deals to date totaling $53 billion. 15 have been >$1 billion with cancer, rare disease & cell therapies some of the areas of interest. ... See MoreSee Less
View on Facebook
AGT CEO, Jeff Galvin, had a chat with social media influencer and HIV advocate, Raif Derrazi, to discuss the latest updates on our AGT103-T clinical trials. Dive into the conversation as they shed light on the research and what lies ahead in our mission to find a cure for HIV! loom.ly/jAThqIU#HIV #hivcure #HIVresearch #clinicaltrials ... See MoreSee Less
View on Facebook
Can genetic evidence make drugs more effective? A new study in Nature suggests YES. Drug mechanisms with genetic support have a 2.6x higher chance of success. loom.ly/NxSxjXk#genetics #science #Healthcare ... See MoreSee Less
View on Facebook